Barclays PLC Has $8.12 Million Stock Position in TG Therapeutics, Inc. (NASDAQ:TGTX)

Barclays PLC lifted its stake in TG Therapeutics, Inc. (NASDAQ:TGTX) by 83.9% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 347,057 shares of the biopharmaceutical company’s stock after buying an additional 158,323 shares during the period. Barclays PLC’s holdings in TG Therapeutics were worth $8,117,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also modified their holdings of the stock. NBC Securities Inc. raised its stake in TG Therapeutics by 58.9% during the third quarter. NBC Securities Inc. now owns 1,309 shares of the biopharmaceutical company’s stock worth $30,000 after acquiring an additional 485 shares in the last quarter. Ashton Thomas Private Wealth LLC bought a new stake in shares of TG Therapeutics in the 2nd quarter worth about $35,000. Blue Trust Inc. grew its holdings in shares of TG Therapeutics by 127.3% in the 3rd quarter. Blue Trust Inc. now owns 1,516 shares of the biopharmaceutical company’s stock worth $35,000 after purchasing an additional 849 shares during the last quarter. ORG Wealth Partners LLC acquired a new stake in shares of TG Therapeutics during the 3rd quarter worth about $53,000. Finally, Values First Advisors Inc. bought a new position in TG Therapeutics during the 3rd quarter valued at about $58,000. Institutional investors own 58.58% of the company’s stock.

TG Therapeutics Stock Down 2.4 %

Shares of TGTX opened at $33.57 on Wednesday. The business’s fifty day moving average price is $29.06 and its two-hundred day moving average price is $23.69. The firm has a market capitalization of $5.23 billion, a price-to-earnings ratio of -335.70 and a beta of 2.25. TG Therapeutics, Inc. has a 52 week low of $12.84 and a 52 week high of $36.84. The company has a debt-to-equity ratio of 1.27, a quick ratio of 3.91 and a current ratio of 4.59.

TG Therapeutics (NASDAQ:TGTX) last posted its quarterly earnings results on Monday, November 4th. The biopharmaceutical company reported $0.02 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.03 by ($0.01). The firm had revenue of $83.90 million during the quarter, compared to the consensus estimate of $81.68 million. TG Therapeutics had a negative net margin of 5.42% and a negative return on equity of 8.32%. TG Therapeutics’s revenue was down 49.4% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.73 EPS. On average, analysts predict that TG Therapeutics, Inc. will post 0.17 earnings per share for the current year.

Insider Activity

In other news, Director Sagar Lonial sold 5,000 shares of the firm’s stock in a transaction on Monday, November 11th. The stock was sold at an average price of $30.44, for a total value of $152,200.00. Following the transaction, the director now directly owns 100,195 shares in the company, valued at $3,049,935.80. This trade represents a 4.75 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders own 10.50% of the company’s stock.

Analysts Set New Price Targets

Several analysts have weighed in on the stock. HC Wainwright upped their price objective on shares of TG Therapeutics from $49.00 to $55.00 and gave the stock a “buy” rating in a research note on Tuesday, November 5th. TD Cowen initiated coverage on TG Therapeutics in a research report on Tuesday, October 29th. They set a “buy” rating and a $50.00 price target on the stock. StockNews.com raised TG Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday. The Goldman Sachs Group boosted their price objective on TG Therapeutics from $20.00 to $22.00 and gave the stock a “neutral” rating in a research note on Tuesday, November 5th. Finally, JPMorgan Chase & Co. raised their target price on TG Therapeutics from $30.00 to $43.00 and gave the company an “overweight” rating in a research note on Monday, November 25th. Two research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $40.67.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.